NCT07522151招募中3 期
A Randomized, Double-blind, Multicenter Phase III Trial of Adebrelimab (SHR-1316) Plus S-1 and Oxaliplatin (SOX) Versus Placebo Plus S-1 and Oxaliplatin in the Perioperative Treatment of Resectable Gastric or Gastroesophageal Junction Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd1 个研究点 分布在 1 个国家目标入组 874 人开始时间: 2026年5月7日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 874
- 试验地点
- 1
- 主要终点
- Investigator-assessed EFS
研究概览
简要总结
This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with pathologically confirmed gastric cancer or gastroesophageal junction cancer.
- •Age: ≥18 years old, <75 years old, both male and female are eligible.
- •Before entering the study, the investigator has evaluated and determined that the subject is suitable and plans to undergo neoadjuvant therapy + radical surgery for curative purposes.
- •Gastric cancer or gastroesophageal junction cancer applicable to the 8th edition of the AJCC gastric cancer staging criteria.
- •Fresh specimens (preferred) or formalin-fixed, paraffin-embedded tumor tissue blocks or unstained tumor specimen sections obtained within 6 months before randomization can be provided.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 -
- •Expected survival ≥ 6 months.
- •Adequate organ and bone marrow function.
- •Female subjects are either infertile or fertile, with a negative serum pregnancy test result within 3 days before the start of study medication and not in the lactation period. Fertile female subjects and male subjects whose partners are fertile must agree to avoid sperm/egg donation from the time of signing the informed consent form until 6 months after the last administration of the investigational drug, and comply with relevant contraceptive requirements.
- •Consent has been obtained from the individual and the informed consent form has been signed, willing and able to comply with planned visits, study treatment, laboratory tests, and other trial procedures.
排除标准
- •Gastric cancer known to be squamous cell carcinoma, undifferentiated carcinoma or other histological types, or adenocarcinoma mixed with other histological types.
- •Gastric esophageal junction cancer, Siewert type I; or Siewert type II with esophageal invasion length ≥ 4 cm; or other cases not suitable for clinical staging assessment using the 8th edition of the AJCC gastric cancer staging criteria, or not suitable for conventional surgical methods or approaches for gastric cancer.
- •The subject's weight has decreased by more than 20% within 2 months before randomization.
- •Previous anti-tumor treatment for gastric cancer/gastric esophageal junction cancer (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy or tumor embolization).
- •Known allergy to any component of the investigational drug (including adibelimab/placebo, tegafur, and oxaliplatin), or allergy to humanized monoclonal antibody products.
- •Diagnosis of any other malignant tumor within 5 years before entering the study, except for locally treatable and cured skin basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma.
- •History of immunodeficiency (including positive HIV test, other acquired or congenital immunodeficiency diseases) or organ transplantation (including allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, etc.); history of active autoimmune disease, except for immune disorders that do not require systemic treatment (such as vitiligo, psoriasis, etc.) or autoimmune diseases that can be improved through hormone replacement therapy (such as type 1 diabetes or hypothyroidism).
- •Severe, unhealed or open wounds, active ulcers, or untreated fractures.
- •Active severe digestive system diseases.
- •Presence of interstitial pneumonia or interstitial lung disease.
- •Severe cardiovascular or metabolic diseases.
- •Active HBV or HCV infection (HBsAg positive and viral copy number ≥ 2000 IU/mL, HCV antibody positive and HCV RNA above the upper limit of normal at the research center), or co-infection with hepatitis B and hepatitis C.
- •Active tuberculosis infection within 1 year before randomization (including but not limited to pulmonary tuberculosis, intestinal tuberculosis, etc.), or a history of active tuberculosis infection more than 1 year ago but without regular treatment.
- •Severe infection within 4 weeks before randomization.
- •Known history of abuse of psychotropic drugs or drug addiction.
- •Presence of other serious physical or mental diseases or abnormal laboratory tests that may increase the risk of participation in the study, or interfere with the study results, and patients considered unsuitable for participation in the study by the investigator.
研究组 & 干预措施
Treatment group B: placebo with SOX.
Experimental
干预措施: Adebrelimab blank preparation plus S-1 and oxaliplatin. (Drug)
Treatment group A: Adebrelimab with SOX.
Experimental
干预措施: Adebrelimab plus S-1 and oxaliplatin (Drug)
结局指标
主要结局
Investigator-assessed EFS
时间窗: About 8 years
Assessments BY INVESTIGATORS
次要结局
- Complete response (pCR) rate as assessed by the Pathology Review Committee (PRC)(About 3 years)
- Rate of pathologically significant response (MPR) as assessed by the Pathology Review Committee (PRC)(About 3 years)
- EFS as assessed by an independent review committee (IRC)(About 8 years)
- DFS, as assessed by investigator /IRC(About 8 years)
- pCR rate by central pathological evaluation(About 3 years)
- R0 resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups(About 8 years)
- D2 radical resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups(About 8 years)
- objective response rate (ORR) of neoadjuvant therapy evaluated by investigators in different treatment groups(About 8 years)
- The incidence of adverse events (AE) were evaluated according to NCI-CTCAE 6.0(About 4 years)
- The severity of serious adverse events (SAE) were evaluated according to NCI-CTCAE 6.0(About 4 years)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
3 期
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsNon-Small Cell Lung CancerNCT07464327Hansoh BioMedical R&D Company450
尚未招募
3 期
A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based TreatmentNCT07392060Shanghai Jiatan Pharmatech Co., Ltd440
招募中
2 期
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.Hepatocellular Carcinoma (HCC)NCT07490262Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.680
招募中
3 期
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerCTRI/2025/02/080765AstraZeneca AB630
招募中
3 期
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)Extensive-stage Small-cell Lung CancerNCT07502300Sichuan Baili Pharmaceutical Co., Ltd.562